Search

Your search keyword '"Schetelig, Johannes"' showing total 801 results
Start Over Author "Schetelig, Johannes" Search Limiters Available in Library Collection
801 results on '"Schetelig, Johannes"'

1. Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence

Author

Eckardt, Jan-Niklas, Hahn, Waldemar, Röllig, Christoph, Stasik, Sebastian, Platzbecker, Uwe, Müller-Tidow, Carsten, Serve, Hubert, Baldus, Claudia D., Schliemann, Christoph, Schäfer-Eckart, Kerstin, Hanoun, Maher, Kaufmann, Martin, Burchert, Andreas, Thiede, Christian, Schetelig, Johannes, Sedlmayr, Martin, Bornhäuser, Martin, Wolfien, Markus, and Middeke, Jan Moritz

Published
2024
Full Text
View/download PDF

2. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial

Author

Al-Sawaf, Othman, Ligtvoet, Rudy, Robrecht, Sandra, Stumpf, Janina, Fink, Anna-Maria, Tausch, Eugen, Schneider, Christof, Boettcher, Sebastian, Mikusko, Martin, Ritgen, Matthias, Schetelig, Johannes, von Tresckow, Julia, Vehling-Kaiser, Ursula, Gaska, Tobias, Wendtner, Clemens Martin, Chapuy, Bjoern, Fischer, Kirsten, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Staber, Philipp, Niemann, Carsten, Hallek, Michael, and Eichhorst, Barbara

Published
2024
Full Text
View/download PDF

3. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

Author

Stilgenbauer, Stephan, Tausch, Eugen, Roberts, Andrew W., Davids, Matthew S., Eichhorst, Barbara, Hallek, Michael, Hillmen, Peter, Schneider, Christof, Schetelig, Johannes, Böttcher, Sebastian, Kater, Arnon P., Jiang, Yanwen, Boyer, Michelle, Popovic, Relja, Ghanim, Majd T., Moran, Michael, Sinai, Wendy J., Wang, Xifeng, Mukherjee, Nabanita, Chyla, Brenda, Wierda, William G., and Seymour, John F.

Published
2024
Full Text
View/download PDF

4. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome

Author

Georgi, Julia-Annabell, Stasik, Sebastian, Eckardt, Jan-Niklas, Zukunft, Sven, Hartwig, Marita, Röllig, Christoph, Middeke, Jan Moritz, Oelschlägel, Uta, Krug, Utz, Sauer, Tim, Scholl, Sebastian, Hochhaus, Andreas, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Hänel, Mathias, Noppeney, Richard, Kaiser, Ulrich, Baldus, Claudia D., Kaufmann, Martin, Müller-Tidow, Carsten, Platzbecker, Uwe, Berdel, Wolfgang E., Serve, Hubert, Ehninger, Gerhard, Bornhäuser, Martin, Schetelig, Johannes, Kroschinsky, Frank, and Thiede, Christian

Published
2023
Full Text
View/download PDF

5. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles

Author

Eckardt, Jan-Niklas, Röllig, Christoph, Metzeler, Klaus, Heisig, Peter, Stasik, Sebastian, Georgi, Julia-Annabell, Kroschinsky, Frank, Stölzel, Friedrich, Platzbecker, Uwe, Spiekermann, Karsten, Krug, Utz, Braess, Jan, Görlich, Dennis, Sauerland, Cristina, Woermann, Bernhard, Herold, Tobias, Hiddemann, Wolfgang, Müller-Tidow, Carsten, Serve, Hubert, Baldus, Claudia D., Schäfer-Eckart, Kerstin, Kaufmann, Martin, Krause, Stefan W., Hänel, Mathias, Berdel, Wolfgang E., Schliemann, Christoph, Mayer, Jiri, Hanoun, Maher, Schetelig, Johannes, Wendt, Karsten, Bornhäuser, Martin, Thiede, Christian, and Middeke, Jan Moritz

Published
2023
Full Text
View/download PDF

6. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome

Author

Eckardt, Jan-Niklas, Stasik, Sebastian, Röllig, Christoph, Sauer, Tim, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Herbst, Regina, Hänel, Mathias, Hanoun, Maher, Kaiser, Ulrich, Kaufmann, Martin, Rácil, Zdenek, Mayer, Jiri, Cerqueira, Tiago, Kroschinsky, Frank, Berdel, Wolfgang E., Serve, Hubert, Müller-Tidow, Carsten, Platzbecker, Uwe, Baldus, Claudia D., Schetelig, Johannes, Siepmann, Timo, Bornhäuser, Martin, Middeke, Jan Moritz, and Thiede, Christian

Published
2023
Full Text
View/download PDF

7. Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy

Author

Zou, Jun, Kongtim, Piyanuch, Srour, Samer A, Greenbaum, Uri, Schetelig, Johannes, Heidenreich, Falk, Baldauf, Henning, Moore, Brandt, Saengboon, Supawee, Carmazzi, Yudith, Rondon, Gabriela, Ma, Qing, Rezvani, Katayoun, Shpall, Elizabeth J, Champlin, Richard E, Ciurea, Stefan O, and Cao, Kai

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Regenerative Medicine, Transplantation, Clinical Research, Humans, Middle Aged, Donor Selection, Transplantation Conditioning, Transplantation, Haploidentical, Receptors, KIR, Cyclophosphamide, haplo-HSCT, NK cell alloreactivity, KIR, donor selection, overall survival, progression-free survival, Immunology, Medical Microbiology, Biochemistry and cell biology, Genetics
Abstract

With the continuous increase in the use of haploidentical donors for transplantation, the selection of donors becomes increasingly important. Haploidentical donors have been selected primarily based on clinical characteristics, while the effects of killer cell immunoglobulin-like receptors (KIRs) on outcomes of haploidentical-hematopoietic stem cell transplantation (haplo-HSCT) with post-transplant cyclophosphamide (PTCy) remain inconclusive. The present study aimed to thoroughly evaluate the effect of KIRs and binding ligands assessed by various models, in addition to other patient/donor variables, on clinical outcomes in haplo-HSCT. In a cohort of 354 patients undergoing their first haplo-HSCT, we found that a higher Count Functional inhibitory KIR score (CF-iKIR) was associated with improved progression-free survival (adjusted hazard ratio [HR], 0.71; P = .029) and overall survival (OS) (HR, 0.66; P = .016), while none of the other models predicted for survival in these patients. Moreover, using exploratory classification and regression tree analysis, we found that donor age 58 years was associated with the worst OS. In the rest of our cohort (80%), cytomegalovirus-reactive recipients with a donor

Published
2022

8. Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML

Author

Fein, Joshua A., Shouval, Roni, Krieger, Elizabeth, Spellman, Stephen R., Wang, Tao, Baldauf, Henning, Fleischhauer, Katharina, Kröger, Nicolaus, Horowitz, Mary, Maiers, Martin, Miller, Jeffrey S, Mohty, Mohamad, Nagler, Arnon, Weisdorf, Daniel, Malmberg, Karl-Johan, Toor, Amir A., Schetelig, Johannes, Romee, Rizwan, and Koreth, John

Published
2024
Full Text
View/download PDF

9. Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation

Author

Story, Charlotte McIlwaine, Wang, Tao, Bhatt, Vijaya Raj, Battiwalla, Minoo, Badawy, Sherif M, Kamoun, Malek, Gragert, Loren, Brown, Valerie, Baxter-Lowe, Lee Ann, Marsh, Steven GE, Gadalla, Shahinaz M, Schetelig, Johannes, Mytilineos, Joannis, Miklos, David, Waller, Edmund K, Kuxhausen, Michelle, Spellman, Stephen, Lee, Stephanie, Paczesny, Sophie, Lansford, Jefferson L, Vincent, Benjamin G, Riches, Marcie L, Armistead, Paul M, and Committee, Center for International Blood and Marrow Transplant Research Immunobiology Working

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Prevention, Transplantation, Clinical Research, Good Health and Well Being, Hematopoietic Stem Cell Transplantation, Humans, Neoplasm Recurrence, Local, Peptides, Retrospective Studies, Unrelated Donors, Center for International Blood and Marrow Transplant Research Immunobiology Working Committee, Graft-versus-host disease, HLA, Minor histocompatibility antigen, Peptide epitope binding, Clinical Sciences, Cardiovascular medicine and haematology
Abstract

Minor histocompatibility antigens (mHAs), recipient-derived peptide epitopes presented on the cell surface, are known to mediate graft-versus-host disease (GVHD); however, there are no current methods to associate mHA features with GVHD risk. This deficiency is due in part to the lack of technological means to accurately predict, let alone confirm, the tremendous number of potential mHAs in each individual transplant. Previous studies have shown that different HLA molecules present varying fractions of candidate peptide epitopes; however, the genetic "distance" between HLA-matched donors and recipients is relatively constrained. From these 2 observations, it is possible that the HLA type for a donor-recipient pair (DRP) would provide a surrogate measurement of the number of predicted mHAs, which could be related to GVHD risk. Because different HLA molecules present variable numbers of peptide antigens, a predicted cumulative peptide-binding efficiency can be calculated for individual DRP based on the pair's HLA type. The purpose of this study was to test whether cumulative peptide-binding efficiency is associated with the risk of acute GVHD (aGVHD) or relapse. In this retrospective Center for International Blood and Marrow Transplant Research study, a total of 3242 HLA-matched DRPs were analyzed for predicted cumulative peptide-binding efficiency using their HLA types and were divided into tertiles based on their scores. Univariable and multivariable analyses was performed to test for associations between cumulative peptide-binding efficiency for DRPs, divided into the HLA-matched related donor (MRD) and HLA-matched unrelated donor (MUD) cohorts, and the primary outcomes of aGVHD and relapse. Secondary outcomes investigated included overall survival, disease-free survival, and transplantation-related mortality. Using a computationally generated peptidome as a test dataset, the tested series of HLA class I displayed peptide-binding frequencies ranging from 0.1% to 3.8% of the full peptidome, and HLA class II molecules had peptide-binding frequencies of 12% to 77% across the HLA-DRB1 allotypes. By increasing binding efficiency tertile, the cumulative incidence of aGVHD at 6 months for MUD patients was 41%, 41%, and 45% for HLA class I (P = .336) and 44%, 41%, and 42% for HLA class II (P = .452). The cumulative incidences of relapse at 3 years for MUD transplant recipients were 36%, 38%, and 38% for HLA class I (P = .533) and 37%, 37%, and 38% for HLA class II (P = .896). The findings were similar for MRD transplant recipients. Multivariable analysis did not identify any impact of peptide-binding efficiency on aGVHD or relapse in MUD or MRD transplant recipients. Whereas GVHD is mediated by minor antigen mismatches in the context of HLA-matched allo-HCT, peptide-binding efficiency, which was used as a surrogate measurement for predicted number of binding antigens, did not provide additional clinical information for GVHD risk assessment. The negative result may be due to the limitations of this surrogate marker, or it is possible that GVHD is driven by a subset of immunogenic mHAs. Further research should be directed at direct mHA epitope and immunogenicity prediction.

Published
2021

10. Following Transplantation for Acute Myelogenous Leukemia, Donor KIR Cen B02 Better Protects against Relapse than KIR Cen B01.

Author

Guethlein, Lisbeth A, Beyzaie, Niassan, Nemat-Gorgani, Neda, Wang, Tao, Ramesh, Vidhyalakshmi, Marin, Wesley M, Hollenbach, Jill A, Schetelig, Johannes, Spellman, Stephen R, Marsh, Steven GE, Cooley, Sarah, Weisdorf, Daniel J, Norman, Paul J, Miller, Jeffrey S, and Parham, Peter

Subjects
Cancer, Rare Diseases, Hematology, Transplantation, Genetics, Genotype, HLA Antigens, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Receptors, KIR, Recurrence, Immunology
Abstract

In the treatment of acute myelogenous leukemia with allogeneic hematopoietic cell transplantation, we previously demonstrated that there is a greater protection from relapse of leukemia when the hematopoietic cell transplantation donor has either the Cen B/B KIR genotype or a genotype having two or more KIR B gene segments. In those earlier analyses, KIR genotyping could only be assessed at the low resolution of gene presence or absence. To give the analysis greater depth, we developed high-resolution KIR sequence-based typing that defines all the KIR alleles and distinguishes the expressed alleles from those that are not expressed. We now describe and analyze high-resolution KIR genotypes for 890 donors of this human transplant cohort. Cen B01 and Cen B02 are the common CenB haplotypes, with Cen B02 having evolved from Cen B01 by deletion of the KIR2DL5, 2DS3/5, 2DP1, and 2DL1 genes. We observed a consistent trend for Cen B02 to provide stronger protection against relapse than Cen B01 This correlation indicates that protection depends on the donor having inhibitory KIR2DL2 and/or activating KIR2DS2, and is enhanced by the donor lacking inhibitory KIR2DL1, 2DL3, and 3DL1. High-resolution KIR typing has allowed us to compare the strength of the interactions between the recipient's HLA class I and the KIR expressed by the donor-derived NK cells and T cells, but no clinically significant interactions were observed. The trend observed between donor Cen B02 and reduced relapse of leukemia points to the value of studying ever larger transplant cohorts.

Published
2021

11. Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia

Author

Heidenreich, Falk, Falk, Bose, Baldauf, Henning, Massalski, Carolin, Schäfer, Gesine, Rücker-Braun, Elke, Altmann, Heidi, Sauter, Jürgen, Solloch, Ute V., Lange, Vinzenz, Stölzel, Friedrich, Röllig, Christoph, Middeke, Jan M., von Bonin, Malte, Thiede, Christian, Schäfer-Eckart, Kerstin, Müller-Tidow, Carsten, Krause, Stefan W., Kraus, Sabrina, Kaufmann, Martin, Hänel, Mathias, Serve, Hubert, Neubauer, Andreas, Bornhäuser, Martin, Schmidt, Alexander H., and Schetelig, Johannes

Published
2023
Full Text
View/download PDF

12. Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight

Author

Schetelig, Johannes, primary, Baldauf, Henning, additional, Heidenreich, Falk, additional, Hoogenboom, Jorinde D., additional, Spellman, Stephen R., additional, Kulagin, Alexander, additional, Schroeder, Thomas, additional, Sengeloev, Henrik, additional, Dreger, Peter, additional, Forcade, Edouard, additional, Vydra, Jan, additional, Wagner-Drouet, Eva Maria, additional, Choi, Goda, additional, Paneesha, Shankara, additional, Miranda, Nuno A. A., additional, Tanase, Alina, additional, de Wreede, Liesbeth C., additional, Lange, Vinzenz, additional, Schmidt, Alexander H., additional, Sauter, Jürgen, additional, Fein, Joshua A., additional, Bolon, Yung-Tsi, additional, He, Meilun, additional, Marsh, Steven G. E., additional, Gadalla, Shahinaz M., additional, Paczesny, Sophie, additional, Ruggeri, Annalisa, additional, Chabannon, Christian, additional, and Fleischhauer, Katharina, additional

Published
2024
Full Text
View/download PDF

13. Macroscopic, histologic, and clinical assessment of acute graft-versus-host disease of the upper gastrointestinal tract within 6 weeks after allogeneic hematopoietic cell transplantation

Author

Sarraf, Abed A., Schetelig, Johannes, Baldauf, Henning, Stölzel, Friedrich, Middeke, Jan Moritz, Sockel, Katja, Teipel, Raphael, Brückner, Stefan, Berning, Marco, Zeissig, Sebastian, Babatz, Jana, Baretton, Gustavo B., Hampe, Jochen, Bornhäuser, Martin, Aust, Daniela, and Schmelz, Renate

Published
2022
Full Text
View/download PDF

14. Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears

Author

Eckardt, Jan-Niklas, Schmittmann, Tim, Riechert, Sebastian, Kramer, Michael, Sulaiman, Anas Shekh, Sockel, Katja, Kroschinsky, Frank, Schetelig, Johannes, Wagenführ, Lisa, Schuler, Ulrich, Platzbecker, Uwe, Thiede, Christian, Stölzel, Friedrich, Röllig, Christoph, Bornhäuser, Martin, Wendt, Karsten, and Middeke, Jan Moritz

Published
2022
Full Text
View/download PDF

15. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Author

Kunadt, Desiree, Stasik, Sebastian, Metzeler, Klaus H., Röllig, Christoph, Schliemann, Christoph, Greif, Philipp A., Spiekermann, Karsten, Rothenberg-Thurley, Maja, Krug, Utz, Braess, Jan, Krämer, Alwin, Hochhaus, Andreas, Scholl, Sebastian, Hilgendorf, Inken, Brümmendorf, Tim H., Jost, Edgar, Steffen, Björn, Bug, Gesine, Einsele, Hermann, Görlich, Dennis, Sauerland, Cristina, Schäfer-Eckart, Kerstin, Krause, Stefan W., Hänel, Mathias, Hanoun, Maher, Kaufmann, Martin, Wörmann, Bernhard, Kramer, Michael, Sockel, Katja, Egger-Heidrich, Katharina, Herold, Tobias, Ehninger, Gerhard, Burchert, Andreas, Platzbecker, Uwe, Berdel, Wolfgang E., Müller-Tidow, Carsten, Hiddemann, Wolfgang, Serve, Hubert, Stelljes, Matthias, Baldus, Claudia D., Neubauer, Andreas, Schetelig, Johannes, Thiede, Christian, Bornhäuser, Martin, Middeke, Jan M., and Stölzel, Friedrich

Published
2022
Full Text
View/download PDF

16. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

Author

Eckardt, Jan-Niklas, Stölzel, Friedrich, Kunadt, Desiree, Röllig, Christoph, Stasik, Sebastian, Wagenführ, Lisa, Jöhrens, Korinna, Kuithan, Friederike, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Herbst, Regina, Hänel, Mathias, Hanoun, Maher, Kaiser, Ulrich, Kaufmann, Martin, Rácil, Zdenek, Mayer, Jiri, Kroschinsky, Frank, Berdel, Wolfgang E., Ehninger, Gerhard, Serve, Hubert, Müller-Tidow, Carsten, Platzbecker, Uwe, Baldus, Claudia D., Schetelig, Johannes, Bornhäuser, Martin, Thiede, Christian, and Middeke, Jan Moritz

Published
2022
Full Text
View/download PDF

17. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

Author

Middeke, Jan M., Metzeler, Klaus H., Röllig, Christoph, Krämer, Michael, Eckardt, Jan-Niklas, Stasik, Sebastian, Greif, Philipp A., Spiekermann, Karsten, Rothenberg-Thurley, Maja, Krug, Utz, Braess, Jan, Krämer, Alwin, Hochhaus, Andreas, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Görlich, Dennis, Sauerland, Cristina, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Hänel, Mathias, Frickhofen, Norbert, Noppeney, Richard, Kaiser, Ulrich, Kaufmann, Martin, Kunadt, Desiree, Wörmann, Bernhard, Sockel, Katja, von Bonin, Malte, Herold, Tobias, Müller-Tidow, Carsten, Platzbecker, Uwe, Berdel, Wolfgang E., Serve, Hubert, Baldus, Claudia D., Ehninger, Gerhard, Schetelig, Johannes, Hiddemann, Wolfgang, Bornhäuser, Martin, Stölzel, Friedrich, and Thiede, Christian

Published
2022
Full Text
View/download PDF

18. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

Author

Taube, Franziska, Georgi, Julia Annabell, Kramer, Michael, Stasik, Sebastian, Middeke, Jan Moritz, Röllig, Christoph, Krug, Utz, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Brümmendorf, Tim H., Naumann, Ralph, Petzold, Andreas, Mulet-Lazaro, Roger, Valk, Peter J.M., Steffen, Björn, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Hänel, Mathias, Noppeney, Richard, Kaiser, Ulrich, Baldus, Claudia D., Kaufmann, Martin, Herold, Sylvia, Stölzel, Friedrich, Sockel, Katja, von Bonin, Malte, Müller-Tidow, Carsten, Platzbecker, Uwe, Berdel, Wolfgang E., Serve, Hubert, Ehninger, Gerhard, Bornhäuser, Martin, Schetelig, Johannes, and Thiede, Christian

Published
2022
Full Text
View/download PDF

19. Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies

Author

Schulz, Felicitas, primary, Jäger, Paul, additional, Tischer, Johanna, additional, Fraccaroli, Alessia, additional, Bug, Gesine, additional, Hausmann, Andreas, additional, Baermann, Ben-Niklas, additional, Tressin, Patrick, additional, Hoelscher, Alexander, additional, Kasprzak, Annika, additional, Nachtkamp, Kathrin, additional, Schetelig, Johannes, additional, Hilgendorf, Inken, additional, Germing, Ulrich, additional, Dietrich, Sascha, additional, and Kobbe, Guido, additional

Published
2024
Full Text
View/download PDF

20. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

Author

Stasik, Sebastian, Eckardt, Jan-Niklas, Kramer, Michael, Röllig, Christoph, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan, Herbst, Regina, Hänel, Mathias, Frickhofen, Norbert, Noppeney, Richard, Kaiser, Ulrich, Baldus, Claudia D., Kaufmann, Martin, Rácil, Zdenek, Platzbecker, Uwe, Berdel, Wolfgang E., Mayer, Jiri, Serve, Hubert, Müller-Tidow, Carsten, Ehninger, Gerhard, Bornhäuser, Martin, Schetelig, Johannes, Middeke, Jan M., and Thiede, Christian

Published
2021
Full Text
View/download PDF

23. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial

Author

Al-Sawaf, Othman, primary, Ligtvoet, Rudy, additional, Robrecht, Sandra, additional, Stumpf, Janina, additional, Fink, Anna-Maria, additional, Tausch, Eugen, additional, Schneider, Christof, additional, Boettcher, Sebastian, additional, Mikusko, Martin, additional, Ritgen, Matthias, additional, Schetelig, Johannes, additional, von Tresckow, Julia, additional, Vehling-Kaiser, Ursula, additional, Gaska, Tobias, additional, Wendtner, Clemens Martin, additional, Chapuy, Bjoern, additional, Fischer, Kirsten, additional, Kreuzer, Karl-Anton, additional, Stilgenbauer, Stephan, additional, Staber, Philipp, additional, Niemann, Carsten, additional, Hallek, Michael, additional, and Eichhorst, Barbara, additional

Published
2023
Full Text
View/download PDF

25. Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells

Author

Nelde, Annika, primary, Schuster, Heiko, additional, Heitmann, Jonas S., additional, Bauer, Jens, additional, Maringer, Yacine, additional, Zwick, Melissa, additional, Volkmer, Jens-Peter, additional, Chen, James Y., additional, Stanger, Anna M. Paczulla, additional, Lehmann, Ariane, additional, Appiah, Bismark, additional, Märklin, Melanie, additional, Rücker-Braun, Elke, additional, Salih, Helmut R., additional, Roerden, Malte, additional, Schroeder, Sarah M., additional, Häring, Max-Felix, additional, Schlosser, Andreas, additional, Schetelig, Johannes, additional, Schmitz, Marc, additional, Boerries, Melanie, additional, Köhler, Natalie, additional, Lengerke, Claudia, additional, Majeti, Ravindra, additional, Weissman, Irving L., additional, Rammensee, Hans-Georg, additional, and Walz, Juliane S., additional

Published
2023
Full Text
View/download PDF

26. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

Author

Rautenberg, Christina, Stölzel, Friedrich, Röllig, Christoph, Stelljes, Matthias, Gaidzik, Verena, Lauseker, Michael, Kriege, Oliver, Verbeek, Mareike, Unglaub, Julia Marie, Thol, Felicitas, Krause, Stefan W., Hänel, Mathias, Neuerburg, Charlotte, Vucinic, Vladan, Jehn, Christian-Friedrich, Severmann, Julia, Wass, Maxi, Fransecky, Lars, Chemnitz, Jens, Holtick, Udo, Schäfer-Eckart, Kerstin, Schröder, Josephine, Kraus, Sabrina, Krüger, William, Kaiser, Ulrich, Scholl, Sebastian, Koch, Kathrin, Henning, Lea, Kobbe, Guido, Haas, Rainer, Alakel, Nael, Röhnert, Maximilian-Alexander, Sockel, Katja, Hanoun, Maher, Platzbecker, Uwe, Holderried, Tobias A. W., Morgner, Anke, Heuser, Michael, Sauer, Tim, Götze, Katharina S., Wagner-Drouet, Eva, Döhner, Konstanze, Döhner, Hartmut, Schliemann, Christoph, Schetelig, Johannes, Bornhäuser, Martin, Germing, Ulrich, Schroeder, Thomas, and Middeke, Jan Moritz

Published
2021
Full Text
View/download PDF

28. Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study

Author

Weller, Jan Frederic, primary, Lengerke, Claudia, additional, Finke, Jürgen, additional, Schetelig, Johannes, additional, Platzbecker, Uwe, additional, Einsele, Hermann, additional, Schroeder, Thomas, additional, Faul, Christoph, additional, Stelljes, Matthias, additional, Dreger, Peter, additional, Blau, Igor W., additional, Wulf, Gerald, additional, Tischer, Johanna, additional, Scheid, Christoph, additional, Elmaagacli, Ahmet, additional, Neidlinger, Helga, additional, Flossdorf, Sarah, additional, Bornhäuser, Martin, additional, Bethge, Wolfgang, additional, Fleischhauer, Katharina, additional, Kröger, Nicolaus, additional, De Wreede, Liesbeth C., additional, and Christopeit, Maximilian, additional

Published
2023
Full Text
View/download PDF

29. P554: RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY OF HYPOMETHYLATING AGENTS WITH OR WITHOUT ELTROMBOPAG IN ELDERLY AML PATIENTS (DELTA)

Author

Sockel, Katja, primary, Mütherig, Anke, additional, Crysandt, Martina, additional, Hänel, Mathias, additional, Noppeney, Richard, additional, Schaefer-Eckart, Kerstin, additional, Kaufmann, Martin, additional, Röllig, Christoph, additional, Schetelig, Johannes, additional, Zukunft, Sven, additional, Fiebig, Frank, additional, Giagounidis, Aristoteles, additional, Scholl, Sebastian, additional, Lück, Andreas, additional, Rieger, Kathrin, additional, Götze, Katharina, additional, Geer, Thomas, additional, Kiewe, Philipp, additional, Müller-Tidow, Carsten, additional, Serve, Hubert, additional, Baldus, Claudia, additional, Kaiser, Ulrich, additional, Mahlmann, Stefan, additional, Schmidt, Burkhard, additional, Parmentier, Stefani, additional, Illmer, Thomas, additional, Seggewiß-Bernhardt, Ruth, additional, Kiani, Alexander, additional, Linde, Hartmut, additional, Dürk, Heinz, additional, Kramer, Michael, additional, Kunadt, Desiree, additional, Schmidt-Brücken, Katharina, additional, Hase, Jana, additional, Helas, Susann, additional, Moritz Middeke, Jan, additional, von Bonin, Malte, additional, Oelschlaegel, Uta, additional, Ehninger, Gerhard, additional, Thiede, Christian, additional, Bornhauser, Martin, additional, and Platzbecker, Uwe, additional

Published
2023
Full Text
View/download PDF

30. P538: FAST-TRACK MEASURABLE RESIDUAL DISEASE DETECTION BY MULTIPARAMETRIC FLOW CYTOMETRY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

Author

Roehnert, Maximilian, primary, Kramer, Michael, additional, Schadt, Jonas, additional, Ensel, Philipp, additional, Roellig, Christoph, additional, Schetelig, Johannes, additional, Stoelzel, Friedrich, additional, Schlenk, Richard, additional, Bornhaueser, Martin, additional, von Bonin, Malte, additional, and Oelschlaegel, Uta, additional

Published
2023
Full Text
View/download PDF

31. S138: VALIDATION OF THE REVISED 2022 EUROPEAN LEUKEMIANET (ELN) RISK STRATIFICATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA

Author

Bill, Marius, primary, Ruhnke, Leo, additional, Zukunft, Sven, additional, Schäfer, Silvia, additional, Eckardt, Jan-Niklas, additional, Stasik, Sebastian, additional, Hanoun, Maher, additional, Schroeder, Thomas, additional, Fransecky, Lars, additional, Steffen, Björn, additional, Krause, Stefan W., additional, Scholl, Sebastian, additional, Hochhaus, Andreas, additional, Sauer, Tim, additional, Kraus, Sabrina, additional, Schäfer-Eckart, Kerstin, additional, Kaufmann, Martin, additional, Jost, Edgar, additional, Brümmendorf, Tim H, additional, Schliemann, Christoph, additional, Mikesch, Jan-Henrik, additional, Krug, Utz, additional, Hänel, Mathias, additional, Morgner, Anke, additional, Schaich, Markus, additional, Neubauer, Andreas, additional, Repp, Roland, additional, Niemann, Dirk, additional, Seggewiss-Bernhardt, Ruth, additional, Meinhardt, Achim, additional, Kullmer, Johannes, additional, Kaiser, Ulrich, additional, Blau, Wolfgang, additional, Kiani, Alexander, additional, Grigoleit, Götz Ulrich, additional, Giagounidis, Aristoteles, additional, Wurm, Alexander, additional, Altmann, Heidi, additional, Middeke, Jan Moritz, additional, Schetelig, Johannes, additional, Müller-Tidow, Carsten, additional, Stölzel, Friedrich, additional, Baldus, Claudia, additional, Platzbecker, Uwe, additional, Serve, Hubert, additional, Bornhäuser, Martin, additional, Thiede, Christian, additional, and Röllig, Christoph, additional

Published
2023
Full Text
View/download PDF

33. Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia

Author

Schetelig, Johannes, de Wreede, Liesbeth C., van Gelder, Michel, Koster, Linda, Finke, Jürgen, Niederwieser, Dietger, Beelen, Dietrich, Mufti, G. J., Platzbecker, Uwe, Ganser, Arnold, Heidenreich, Silke, Maertens, Johan, Socié, Gerard, Brecht, Arne, Stelljes, Matthias, Kobbe, Guido, Volin, Liisa, Nagler, Arnon, Vitek, Antonin, Luft, Thomas, Ljungman, Per, Yakoub-Agha, Ibrahim, Robin, Marie, and Kröger, Nicolaus

Published
2019
Full Text
View/download PDF

34. Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia—Lessons Learned from the Prospective BRIDGE Trial

Author

Middeke, Jan Moritz, Herbst, Regina, Parmentier, Stefani, Bug, Gesine, Hänel, Mathias, Stuhler, Gernot, Schäfer-Eckart, Kerstin, Rösler, Wolf, Klein, Stefan, Bethge, Wolfgang, Bitz, Ulrich, Büttner, Bozena, Knoth, Holger, Alakel, Nael, Schaich, Markus, Morgner, Anke, Kramer, Michael, Sockel, Katja, von Bonin, Malte, Stölzel, Friedrich, Platzbecker, Uwe, Röllig, Christoph, Thiede, Christian, Ehninger, Gerhard, Bornhäuser, Martin, and Schetelig, Johannes

Published
2017
Full Text
View/download PDF

37. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features

Author

Rasche, Leo, Röllig, Christoph, Stuhler, Gernot, Danhof, Sophia, Mielke, Stephan, Grigoleit, Goetz Ulrich, Dissen, Lea, Schemmel, Lea, Middeke, Jan Moritz, Rücker, Viktoria, Schreder, Martin, Schetelig, Johannes, Bornhäuser, Martin, Einsele, Hermann, Thiede, Christian, and Knop, Stefan

Published
2016
Full Text
View/download PDF

39. Specific Class I HLA Supertypes but Not HLA Zygosity or Expression Are Associated with Outcomes following HLA-Matched Allogeneic Hematopoietic Cell Transplant: HLA Supertypes Impact Allogeneic HCT Outcomes

Author

Camacho-Bydume, Christine, Wang, Tao, Sees, Jennifer A., Fernandez-Viña, Marcelo, Abid, Muhammad Bilal, Askar, Medhat, Beitinjaneh, Amer, Brown, Valerie, Castillo, Paul, Chhabra, Saurabh, Gadalla, Shahinaz M., Hsu, Jing-Mei, Kamoun, Malek, Lazaryan, Aleksandr, Nishihori, Taiga, Page, Kristin, Schetelig, Johannes, Fleischhauer, Katharina, Marsh, Steven G.E., Paczesny, Sophie, Spellman, Stephen R., Lee, Stephanie J., and Hsu, Katharine C.

Published
2021
Full Text
View/download PDF

40. Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial

Author

Ruhnke, Leo, primary, Röllig, Christoph, additional, Herold, Sylvia, additional, Sauer, Tim, additional, Brandts, Christian H, additional, Steffen, Björn, additional, Schäfer-Eckart, Kerstin, additional, Krause, Stefan W, additional, Hänel, Mathias, additional, Reichle, Albrecht, additional, Scholl, Sebastian, additional, Neubauer, Andreas, additional, Mikesch, Jan-Henrik, additional, Schetelig, Johannes, additional, Stölzel, Friedrich, additional, Kramer, Michael, additional, Haake, Annett, additional, Frimmel, Julia, additional, Krämer, Alwin, additional, Schlenk, Richard, additional, Platzbecker, Uwe, additional, Serve, Hubert, additional, Baldus, Claudia D, additional, Müller-Tidow, Carsten, additional, Aust, Daniela, additional, Bornhäuser, Martin, additional, Ehninger, Gerhard, additional, and Thiede, Christian, additional

Published
2023
Full Text
View/download PDF

41. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD

Author

Ho, Anthony D., Schetelig, Johannes, Bochtler, Tilmann, Schaich, Markus, Schäfer-Eckart, Kerstin, Hänel, Mathias, Rösler, Wolf, Einsele, Hermann, Kaufmann, Martin, Serve, Hubert, Berdel, Wolfgang E., Stelljes, Matthias, Mayer, Jiri, Reichle, Albrecht, Baldus, Claudia D., Schmitz, Norbert, Kramer, Michael, Röllig, Christoph, Bornhäuser, Martin, Thiede, Christian, and Ehninger, Gerhard

Published
2016
Full Text
View/download PDF

42. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients with Intermediate-Risk Acute Myeloid Leukemia : A Randomized Clinical Trial

Author

Bornhäuser, Martin, Schliemann, Christoph, Schetelig, Johannes, Röllig, Christoph, Kramer, Michael, Glass, Bertram, Platzbecker, Uwe, Burchert, Andreas, Hänel, Mathias, Müller, Lutz P., Klein, Stefan, Bug, Gesine, Beelen, Dietrich, Rösler, Wolf, Schäfer-Eckart, Kerstin, Schmid, Christoph, Jost, Edgar, Lenz, Georg, Tischer, Johanna, Spiekermann, Karsten, Pfirrmann, Markus, Serve, Hubert, Stölzel, Friedrich, Alakel, Nael, Middeke, Jan Moritz, Thiede, Christian, Ehninger, Gerhard, Berdel, Wolfgang E., and Stelljes, Matthias

Subjects
Cancer Research, Oncology, Medizin
Abstract

ImportanceThe ideal postremission strategy in intermediate-risk acute myeloid leukemia (AML) in first complete remission (CR) has been a matter of debate.ObjectiveTo explore the optimal therapy for patients with intermediate-risk AML after first complete remission.Design, Settings, and ParticipantsThis investigator-initiated, open-label, 2-armed, phase 3 randomized clinical trial assessed patients at 16 hospitals in Germany from February 2, 2011, until July 1, 2018. Key eligibility criteria included cytogenetically defined intermediate-risk AML according to Medical Research Council classification, first CR or CR with incomplete blood cell count recovery after conventional induction therapy, age of 18 to 60 years, and availability of a human leukocyte antigen (HLA)–matched sibling or unrelated donor. A detailed statistical analysis plan was written and finalized on July 7, 2020. Data were exported for analysis on April 13, 2021.InterventionsPatients were randomized 1:1 to receive allogeneic hematopoietic cell transplantation (HCT) or high-dose cytarabine for consolidation and salvage HCT only in case of relapse. Strata for randomization included age (18-40 vs 41-60 years), NPM1 and CEBPA variation status, and donor type (unrelated vs related).Main Outcomes and MeasuresEnd points included overall-survival as the primary outcome and disease-free survival, cumulative incidence of relapse, treatment-related mortality, and quality of life measured according to the Medical Outcomes Study 36-Item Short-Form Health Survey as secondary outcomes.ResultsA total of 143 patients (mean [SD] age, 48.2 [9.8] years; 81 [57%] male) with AML who fulfilled the eligibility criteria were randomized. In the intention-to-treat analysis, the probability of survival at 2 years was 74% (95% CI, 62%-83%) after primary allogeneic HCT and 84% (95% CI, 73%-92%) after consolidation chemotherapy (P = .22). Disease-free survival after HCT at 2 years was 69% (95% CI, 57%-80%) compared with 40% (95% CI, 28%-53%) after consolidation chemotherapy (P = .001). Allogeneic HCT during the first CR was associated with a cumulative incidence of relapse at 2 years of 20% (95% CI, 13%-31%) compared with 58% (95% CI, 47%-71%; P P = .005). Similar outcomes were observed when analyses were confined to the 96 patients at intermediate risk according to the European Leukemia Network classification. Most importantly, all 41 patients relapsing after consolidation chemotherapy (36 hematologic, 4 molecular, and 1 extramedullary) proceeded to allogeneic HCT. No significant differences in health-related quality of life measures were observed between groups.Conclusions and RelevancePrimary allogeneic HCT during first CR was not associated with superior overall survival compared with consolidation chemotherapy in patients 60 years or younger with intermediate-risk AML during the first CR and an available donor.Trial RegistrationClinicalTrials.gov Identifier: NCT01246752

Published
2023

44. Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societé Française de Greffe de Moelle et Therapie Cellulaire

Author

Xavier, Erick, Cornillon, Jérôme, Ruggeri, Annalisa, Chevallier, Patrice, Cornelissen, Jan J., Andersen, Niels S., Maillard, Natacha, Nguyen, Stephanie, Blaise, Didier, Deconinck, Eric, Veelken, Hendrik, Milpied, Noel, Van Gelder, Michel, Peffault de Latour, Regis, Gluckman, Eliane, Kröger, Nicolaus, Schetelig, Johannes, and Rocha, Vanderson

Published
2015
Full Text
View/download PDF

45. Comparison of Unrelated Cord Blood and Peripheral Blood Stem Cell Transplantation in Adults with Myelodysplastic Syndrome after Reduced-Intensity Conditioning Regimen: A Collaborative Study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party

Author

Robin, Marie, Ruggeri, Annalisa, Labopin, Myriam, Niederwieser, Dietger, Tabrizi, Reza, Sanz, Guillermo, Bourhis, Jean-Henri, van Biezen, Anja, Koenecke, Christian, Blaise, Didier, Tischer, Johanna, Craddock, Charles, Maillard, Natacha, Mohty, Mohamad, Russel, Nigel, Schetelig, Johannes, Finke, Jürgen, Gluckman, Eliane, de Witte, Theo M., Rocha, Vanderson, and Kroger, Nicolaus

Published
2015
Full Text
View/download PDF

46. Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

Author

Röllig, Christoph, primary, Steffen, Björn, additional, Schliemann, Christoph, additional, Mikesch, Jan-Henrik, additional, Alakel, Nael, additional, Herbst, Regina, additional, Haenel, Mathias, additional, Noppeney, Richard, additional, Hanoun, Maher, additional, Kaufmann, Martin, additional, Racil, Zdenek, additional, Schäfer-Eckart, Kerstin, additional, Sauer, Tim, additional, Neubauer, Andreas, additional, Baldus, Claudia D., additional, Mertova, Jolana, additional, Jost, Edgar, additional, Niemann, Dirk, additional, Novak, Jan, additional, Krause, Stefan W., additional, Scholl, Sebastian, additional, Hochhaus, Andreas, additional, Held, Gerhard, additional, Szotkowski, Tomáš, additional, Schmid, Christoph, additional, Rank, Andreas, additional, Fransecky, Lars, additional, Kramer, Michael, additional, Fiebig, Frank, additional, Haake, Annett, additional, Stoelzel, Friedrich, additional, Schetelig, Johannes, additional, Middeke, Jan Moritz, additional, Platzbecker, Uwe, additional, Thiede, Christian, additional, Müller-Tidow, Carsten, additional, Berdel, Wolfgang E., additional, Serve, Hubert, additional, Ehninger, Gerhard, additional, Mayer, Jiří, additional, and Bornhaeuser, Martin, additional

Published
2022
Full Text
View/download PDF

47. Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

Author

Niederwieser, Dietger, primary, Hasenclever, Dirk, additional, Berdel, Wolfgang E., additional, Biemond, Bart J., additional, Al-Ali, Haifa Kathrin, additional, Chalandon, Yves, additional, Van Gelder, Michel, additional, Junghanss, Christian, additional, Gahrton, Goesta, additional, Haenel, Mathias, additional, Hehlmann, Rüdiger, additional, Heinicke, Thomas, additional, Hochhaus, Andreas, additional, Iacobelli, Simona, additional, Kooy, Rien van Marwijk, additional, Kröger, Nicolaus, additional, Janssen, Jeroen J.W.M., additional, Jentzsch, Madlen, additional, Breywisch, Frank, additional, Mohty, Mohamad, additional, Masouridi-Levrat, Stavroula, additional, Ossenkoppele, Gert, additional, Passweg, Jakob, additional, Pönisch, Wolfram, additional, Schetelig, Johannes, additional, Schliemann, Christoph, additional, Schwind, Sebastian, additional, Stelljes, Matthias, additional, Valk, Peter JM, additional, Lowenberg, Bob, additional, and Cornelissen, Jan J., additional

Published
2022
Full Text
View/download PDF

48. In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial

Author

Stelljes, Matthias, primary, Middeke, Jan Moritz, additional, Bug, Gesine, additional, Wagner, Eva-Maria, additional, Mueller, Lutz Peter, additional, Christoph, Schmid, additional, Krause, Stefan W., additional, Bethge, Wolfgang, additional, Jost, Edgar, additional, Platzbecker, Uwe, additional, Klein, Stefan, additional, Schubert, Jörg, additional, Niederland, Judith, additional, Kaufmann, Martin, additional, Schäfer-Eckart, Kerstin, additional, Schaich, Markus, additional, Baldauf, Henning, additional, Stölzel, Friedrich, additional, Petzold, Cathleen, additional, Röllig, Christoph, additional, Alakel, Nael, additional, Steffen, Björn, additional, Hauptrock, Beate, additional, Reicherts, Christian, additional, Schliemann, Christoph, additional, Serve, Hubert, additional, Schmidt, Alexander H., additional, Bornhäuser, Martin, additional, Mikesch, Jan-Henrik, additional, and Schetelig, Johannes, additional

Published
2022
Full Text
View/download PDF

49. Fast-Track Measurable Residual Disease Detection By Multiparametric Flow Cytometry in Acute Myeloid Leukemia before Allogeneic Hematopoietic Cell Transplantation

Author

Röhnert, Maximilian Alexander, primary, Kramer, Michael, additional, Schadt, Jonas, additional, Ensel, Philipp, additional, Röllig, Christoph, additional, Schetelig, Johannes, additional, Stölzel, Friedrich, additional, Bornhaeuser, Martin, additional, Oelschlägel, Uta, additional, and von Bonin, Malte, additional

Published
2022
Full Text
View/download PDF

50. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from Different Donor Types in Primary Refractory Acute Myeloid Leukemia: A Report from the ALWP of the EBMT

Author

Barbullushi, Kordelia, primary, Labopin, Myriam, additional, Kröger, Nicolaus, additional, Finke, Jürgen, additional, Stelljes, Matthias, additional, Ganser, Arnold, additional, Bethge, Wolfgang, additional, Einsele, Hermann, additional, Schetelig, Johannes, additional, Fanin, Renato, additional, Jindra, Pavel, additional, Casper, Jochen, additional, Schroeder, Thomas, additional, Edinger, Matthias, additional, Passweg, Jakob, additional, Forcade, Edouard, additional, Tischer, Johanna, additional, Nagler, Arnon, additional, Ciceri, Fabio, additional, and Mohty, Mohamad, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results